Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (UV1-hTERT2012L)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01789099
Recruitment Status : Unknown
Verified May 2021 by Ultimovacs ASA.
Recruitment status was:  Active, not recruiting
First Posted : February 11, 2013
Last Update Posted : May 17, 2021
Oslo University Hospital
Information provided by (Responsible Party):
Ultimovacs ASA

Brief Summary:

In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed. The purpose of this study is to select a biological dose of peptides for further clinical trials. Study recruitment completed at 6 patients in every dose level.

The main study treatment phase of this study is completed and will be reported separately.

Follow-up is ongoing

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer Biological: UV1 synthetic peptide vaccine and GM-CSF Phase 1 Phase 2

Detailed Description:

This is an open label dose-escalating phase I/IIa study of UV1 peptide vaccination in patients with NSCLC after completion of radiation therapy and/or chemotherapy. Patients will be enrolled in this study if they have achieved complete response (CR), partial response (PR) or stable disease (SD) at least 4 weeks after completion of standard first line therapy.

The following 2-step design will be used:

  1. Conventional dose escalation with at least 3 patients per dose level (3 selected dose levels).
  2. Expansion of each dose level to a total of 6 patients for assessment of immune response levels.

13 UV1 vaccinations will be given during the first 6 months (week 26) of treatment, unless clinical deterioration or unacceptable toxicity is encountered. Granulocyte-macrophage colony-stimulating factor (GM-CSF) (Leukine ®) will be used as adjuvant for 11 of the 13 doses of UV1.

After completion of the main study treatment period at week 26, if the patient agrees, additional vaccinations may be considered for the following patients:

  • Immune responders within first 6 months
  • Immune non-responders providing they have at least SD

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
Actual Study Start Date : April 8, 2013
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: UV1 synthetic peptide vaccine and GM-CSF
GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
Biological: UV1 synthetic peptide vaccine and GM-CSF
Other Names:
  • UV1
  • Leukine

Primary Outcome Measures :
  1. Assessment of safety and tolerability of UV1. [ Time Frame: up to 2 years and 3 months. ]
    Frequency and severity of adverse events and serious adverse events. Biochemistry and hematology results, vital signs and ECOG performance status will be assessed.

  2. Immunological response [ Time Frame: Up to 2 years and 3 months. ]
    Number of T-cell responses including time to T-cell responses (up to 6 months), level of response and duration of response.

Secondary Outcome Measures :
  1. Assessment of anti tumor activity [ Time Frame: Up to 2 years and 3 months ]
    Tumor response and progression free survival (PFS)

  2. Selection of biological dose of peptides for further clinical trials. [ Time Frame: Up to 2 years and 3 months ]
    Safety profile and immunological responses of each dose level.

Other Outcome Measures:
  1. Potential correlation between human cytomegalovirus status and immune response [ Time Frame: Up to 2 years and 3 months ]
    Determination of human cytomegalovirus (CMV) status

  2. Further characterization of the immune reaction triggered by the treatment. [ Time Frame: Up to 2 years and 3 months ]
    Extended immunological analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with Non Small Cell Lung Cancer (NSCLC) who has been treated with palliative radiotherapy and/or at least three courses of chemotherapy, and has achieved stable disease (SD), partial response (PR) or complete response (CR) confirmed by CT scan at least 4 weeks after end of treatment. Previous curative radiotherapy is allowed as long as the patient has relapsed and received palliative chemotherapy.
  • No evidence of disease progression at the time of inclusion
  • Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Must be at least 18 years of age.
  • Must have lab values as follows:
  • White Blood Cells ≥ 1.5 x 109/L
  • Platelets ≥ 100 x 109/L
  • Hemoglobin ≥ 9g/dL (≥ 5.6 mmol/L)
  • Creatinine ≥ 140 µmol/L
  • Bilirubin < 20% above the upper limit of normal
  • ASAT and ALAT ≤ 2.5 the upper limit of normal
  • Albumin ≥ 2.5 g/L
  • Signed informed consent

Exclusion Criteria:

  • History of other prior malignancy, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, cervical cancer stage IB or effectively treated malignancy that has been in remission for over 5 years and is highly likely to have been cured.
  • Treatment with any other investigational medicinal product (IMP) within 4 weeks prior to first administration of study drug.
  • Adverse reactions to vaccines such as anaphylaxis or other serious reactions.
  • History of immunodeficiency or autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, sclerodermia, polymyositis-dermatomyositis, juvenile onset insulin-dependent diabetes, or a vasculitic syndrome.
  • Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia.
  • Known active CNS metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may however participate provided they meet the following criteria:

    1. Inactive metastases (without evidence of progression which is documented by CT or MRI within 4 weeks prior to the planned study treatment date), and
    2. If prednisolone or equivalent treatment is required; no more </=10mg/day is permitted.
  • Active infection requiring antibiotic therapy.
  • Pregnancy or lactation.
  • Woman of childbearing potential not using any reliable and adequate contraceptive methods defined as use of oral, implanted, injectable, and mechanical or barrier products for the prevention of pregnancy.
  • Known hypersensitivity to any of the components of the vaccine
  • Known hypersensitivity to Leukine®, yeast derived products or any component of the product
  • Patients who test positive for hepatitis B, C or HIV.
  • Any other anti-tumor treatment within 4 weeks of study entry (including chemotherapy, immunotherapy, endocrine therapy, cytokines, interferons, protease inhibitors and gene therapy).
  • Use of not permitted concomitant medication:
  • chronic corticosteroids except for asthma inhalers / topical use
  • any agent with a known effect on the immune system, unless it is being given at dose levels that are not immunosuppressive, e.g. prednisone at 10mg/day or less.
  • any alternative and complementary drugs that may affect the immune system or be potentially harmful to patients participating in phase I studies.
  • Any reason why, in the opinion of the investigator, the patient should not participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01789099

Layout table for location information
Oslo University Hospital
Oslo, Norway, 0424
Sponsors and Collaborators
Ultimovacs ASA
Oslo University Hospital
Layout table for investigator information
Principal Investigator: Paal F. Brunsvig, MD PhD Oslo University Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ultimovacs ASA Identifier: NCT01789099    
Other Study ID Numbers: 2012-001852-20
First Posted: February 11, 2013    Key Record Dates
Last Update Posted: May 17, 2021
Last Verified: May 2021
Keywords provided by Ultimovacs ASA:
Lung cancer
Peptide vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Immunologic Factors
Physiological Effects of Drugs